跳至主要内容
临床试验/NCT00091637
NCT00091637已完成3 期

APEX-AMI - Pexelizumab in Conjunction With Angioplasty

Procter and Gamble343 个研究点 分布在 1 个国家目标入组 5,745 人开始时间: 2004年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
5,745
试验地点
343
主要终点
Reduction of all causes of mortality

研究概览

简要总结

In the setting of reperfusion therapy in an acute myocardial infarction using primary percutaneous intervention (PCI), the body's own inflammatory system involving the complement cascade may be harmful. This study will test the safety and efficacy of a novel complement inhibitor, pexelizumab to reduce mortality at 30 days.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Cardiac symptoms for at least 20 minutes within past 6 hours;
  • Will undergo primary PCI;
  • Has ECG evidence of acute high risk ST elevation myocardial infarction;
  • Willing and able to be followed for at least 12 months.

排除标准

  • Isolated low risk inferior wall myocardial infarction;
  • Received fibrinolytic therapy;
  • History of complement deficiency;
  • Suspected neisserial infection;
  • Participating in other investigational study;
  • Pregnancy;
  • Previous enrollment.

研究组 & 干预措施

1

Placebo Comparator

Placebo infusion

干预措施: Placebo infusion (Drug)

2

Experimental

Pexelizumab infusion

干预措施: Pexelizumab (Drug)

结局指标

主要结局

Reduction of all causes of mortality

时间窗: day 30

次要结局

未报告次要终点

研究者

发起方
Procter and Gamble
申办方类型
Industry

研究点 (343)

Loading locations...

相似试验